Akari Therapeutics Announces CMO Departure, Appoints Interim

TL;DR

CMO out, interim in at Akari Therapeutics. No major financial details on exit costs yet.

AI Summary

Akari Therapeutics Plc announced on May 1, 2024, the departure of its Chief Medical Officer, Dr. Robert James, and the appointment of Dr. Jonathan Solomon as interim Chief Medical Officer. The company also reported on costs associated with exit or disposal activities, though specific financial figures for these activities were not detailed in this filing.

Why It Matters

Changes in key executive positions like the Chief Medical Officer can signal shifts in strategic direction or operational focus for a biotechnology company.

Risk Assessment

Risk Level: medium — Executive changes and unspecified exit costs introduce uncertainty regarding the company's leadership and financial health.

Key Players & Entities

• Akari Therapeutics Plc (company) — Registrant
• Dr. Robert James (person) — Departing Chief Medical Officer
• Dr. Jonathan Solomon (person) — Appointed interim Chief Medical Officer
• May 1, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — tal Market Ordinary Shares, par value $0.0001 per share* *Trading, but only in conn
• $3.1 million — ts, to be in the range of approximately $3.1 million to $3.2 million, which includes approxi
• $3.2 m — range of approximately $3.1 million to $3.2 million, which includes approximately $1.
• $1.6 million — 2 million, which includes approximately $1.6 million of non-cash expenses related to vesting

Filing Documents

• aktx-20240501.htm (8-K) — 53KB
• 0000950170-24-054726.txt ( ) — 273KB
• aktx-20240501.xsd (EX-101.SCH) — 95KB
• aktx-20240501_htm.xml (XML) — 6KB

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities. On May 1, 2024, Akari Therapeutics, Plc (the "Company") began to implement a reduction-in-force of approximately 67% of its total workforce as a result of the recently announced program prioritization under which the Company's HSCT-TMA program was suspended. The reduction-in-force is part of an operational restructuring plan and includes the elimination of certain senior management positions. The purpose of the restructuring plan, including the reduction-in-force, is to reduce HSCT-TMA related operating costs, while supporting the execution of the Company's long-term strategic plan. The Company currently expects expenses related to the reduction-in-force, consisting primarily of cash severance and termination benefits and related costs, to be in the range of approximately $3.1 million to $3.2 million, which includes approximately $1.6 million of non-cash expenses related to vesting of equity awards. The Company expects these costs to be payable through the fourth quarter of 2024. These estimates are subject to a number of assumptions, and actual results may differ. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the operational restructuring plan, including the reduction-in-force.

02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On May 7, 2024, Rachelle Jacques resigned from the Board of Directors (the "Board"), effective May 7, 2024. In connection with Ms. Jacques' resignation from the Board, the Board reduced its size to five members. There was no disagreement between Ms. Jacques and the Company on any matter related to the Company's operations, policies or practices that led to Ms. Jacques' resignation from the Board. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the expected costs and timing associated with reduction-in-force and expected reductions of operating expenses. These forward-looking statements are based on the Company's current expectations and inherently involve significant risks and uncertainties. The Company's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to cost reduction efforts. In addition, the Company's costs may be greater than anticipated and the workforce and operating expense reductions may have an adverse impact on the Company's development activities. Additionally, these forward-looking statements should be considered in conjunction with the cautionary statements and risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and its other filings filed from time to time with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statement, except as required by law. No Offer or Solicitation This communication is not intended to and shall not constitute an offer to subs

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Akari Therapeutics, Plc Date: May 7, 2024 By: /s/ Samir R. Patel, M.D. Samir R. Patel, M.D. Interim President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR